A Newcastle biotech, specialising in nanorobotic technology to improve the diagnosis of some of the world’s most serious diseases, has joined Newcastle Helix.
Nanovery, a biotechnology company formed in 2018, are developing nanorobots for a quick and easy test to help in the diagnosis of cancer and other diseases. The test is based on DNA nanotechnology and costs less than tissue biopsy, whilst reducing risk to patients.